Informed Prostate Cancer Patient Support

Breaking Down the Barriers: New Ways to Understand Your Pathology Report How AI and innovative clinics are helping prostate cancer patients decode their test results You're Not Alone in Your Confusion If you've ever stared at your pathology report feeling confused and anxious, you're definitely not alone. Thanks to the 21st Century Cures Act, we now receive our test results through patient portals as soon as they're ready—often before our doctors have even seen them. While this gives us faster access to information, it can also leave us trying to decode medical reports that weren't written with patients in mind. Ted, a prostate cancer patient, knows this feeling all too well. He got his biopsy results on a Friday afternoon through his patient portal. "I saw carcinoma and I went, 'Holy [expletive], I have cancer,'" he shared during a recent webinar. "My first thought was, 'Okay, what do I do now?'" Despite calling his urologi...

New Hope for Aggressive Prostate Cancer: Advances in Understanding and Treating Neuroendocrine Prostate Cancer Revolutionary diagnostic tools and promising new therapies offer renewed hope for patients with treatment-resistant disease What Patients Need to Know For most men with prostate cancer, treatments targeting the androgen receptor (AR) pathway—including hormone therapy and newer drugs like enzalutamide and abiraterone—are highly effective. However, as these treatments have become more successful, doctors have observed an important but concerning phenomenon: some cancers develop resistance by essentially changing their identity. This transformation, called neuroendocrine prostate cancer (NEPC), represents one of the most aggressive forms of the disease. At the recent 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Himisha Beltran from Dana-Farber Cancer Institute presented groundbreaking research that offers new hope for patients facing this challenging ...

Evidence and Rationale for Prostate Cancer Screening: Latest Research and Guidelines Bottom Line Up Front: Current evidence strongly supports PSA-based screening for men aged 55-69, with new research showing promising advances in MRI-targeted biopsies, novel biomarkers, and risk-adapted screening strategies that may significantly reduce overdiagnosis while maintaining mortality benefits. The Foundation: Why Screening Matters PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened, according to the U.S. Preventive Services Task Force. At a follow-up of 16 years, the number of patients had dropped even further to 18 men needed to be treated to prevent one death from prostate cancer, demonstrating that screening benefits increase significantly with longer follow-up periods. The mortality reduction is even more impressive in some studies. The Swedish part of the ERSPC trial (Göt...

Revolutionary Advances in Prostate Cancer Radiation Therapy: The Future is Here TL;DR: New adaptive radiation therapy technologies are dramatically improving treatment precision and reducing side effects for prostate cancer patients through real-time imaging guidance and daily treatment plan adjustments. Precision Medicine Transforms Prostate Cancer Treatment Prostate cancer patients now have access to the most advanced radiation therapy techniques in medical history. Recent research published in the International Journal of Radiation Oncology reveals how image-guided adaptive radiation therapy has evolved from basic 2-dimensional planning to sophisticated real-time treatment adjustments that protect healthy tissue while maximizing cancer destruction. What is Adaptive Radiation Therapy? Adaptive radiation therapy represents a quantum leap forward in cancer treatment precision. Unlike traditional radiation therapy that uses fixed treatment plans, adaptive therapy adjusts the radia...